Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.
Approval Alert | Sunvozertinib in EGFR Exon 20+ NSCLC
Advertisement
Advertisement
Trending on CancerNetwork
1
Mosunetuzumab Treatment Combo Yields Responses in High-Risk MCL
2
Dara-KRd Regimen Displays Prolonged PFS in Newly Diagnosed Multiple Myeloma
3
Giredestrant Combo Significantly Boosts PFS in ER+ Advanced Breast Cancer
4
Optimizing the Timing of Genetic Testing in Advanced Ovarian Cancer
5
